Forensic Analysis · Materials / Mining & Chemicals · as of Sep 24, 2026
Chemours Co (CC)
A forensic read on Chemours Co built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Grey Zone
Financial health
1.8
Distress distance
Clean
Earnings quality
5
Forensic signals
-7.2
P / E (ttm)
$2.2B
Market cap
3.79%
Dividend yield
0.4%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Chemours Co earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 1.8, placing it in the Grey zone. 5 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-0.1%
FY2025
Return on invested capital.Return on invested capital is -0.1% in the latest fiscal year, against -2% in FY2023, having run between -1.9% and 4.8% across FY2023–FY2025 with no direction held. The capital base behind it grew +10% across FY2023–FY2025, from $4.6B to $5.1B, and the return did not fall doing it, so the dollars added over that window earned at least the -2% the older base was already earning.
$56M
FY2024–FY2024
Goodwill impairments.Took $56M of goodwill writedowns across 1 year (FY2024 ($56M)) — about 81% of net income over the span. A large writedown means an acquisition turned out worth far less than was paid — a real mark against M&A discipline.
+0.4%/yr
FY2023–FY2025
Share count.Diluted share count changed +1% over the last 2 years to FY2025 (+0.4%/yr). Roughly flat — the count is neither shrinking nor growing meaningfully. Per-share value isn't being meaningfully helped or hurt by the count.
153% of FCF
FY2025
Shareholder returns.Returned $78M to shareholders (buybacks + dividends) in FY2025 — 153% of free cash flow, but 30% of operating cash flow. Returns run ahead of free cash flow, with the gap funded by debt or cash reserves rather than the cash the business itself throws off; the payout itself is still covered by operating cash. Counting the $21M of stock-based comp paid out in shares on top of that, the combined claim on free cash flow is 194%.
-47%
FY2024→FY2025
Key fundamentals
Latest Revenue$5.81B
Revenue Growth YoY+0.4%
Revenue CAGR (2yr)-2.2%
Net Margin-6.6%
Free Cash Flow$51.0M
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Chemours Co's actual 10-K/10-Q/8-K filings?